Stock Events

Stock Events

Chugai Pharmaceutical 

¥8,815
92
+¥55+0.63% Today

Statistics

Day High
8,914
Day Low
8,681
52W High
10,455
52W Low
6,011
Volume
1,105,436,300
Avg. Volume
-
Mkt Cap
14.8T
P/E Ratio
15.51
Dividend Yield
1.51%
Dividend
133.52

Upcoming

30
JUN
Dividend Ex
Decreased
 
31
DEC
Dividend Ex
 
30
JUN 27
Dividend Ex
Estimated
 
31
DEC 27
Dividend Ex
Estimated
 

Dividends

1.51%Dividend Yield
Mar 26
¥72
Mar 26
¥75
Aug 25
¥50
Aug 25
¥75
Mar 25
¥57
10Y Growth
18.04%
5Y Growth
4.39%
3Y Growth
14.12%
1Y Growth
-53.93%

Earnings

24AprExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
0.34
0.4
0.46
0.52
Expected EPS
0.418056573182
Actual EPS
N/A

Financials

33.09%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
2.34TRevenue
774.63BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4519.TSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap156.77B
Pfizer Inc. competes in various therapeutic areas including oncology, vaccines, and immunology, similar to Chugai's focus areas.
Merck
MRK
Mkt Cap294.39B
Merck & Co., Inc. is a direct competitor in the oncology and immunology sectors, areas where Chugai is actively developing treatments.
Novartis
NVS
Mkt Cap293.34B
Novartis AG operates in the same therapeutic areas as Chugai, including oncology and rheumatology, making it a strong competitor.
Johnson & Johnson
JNJ
Mkt Cap564.35B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the oncology, immunology, and neuroscience sectors.
Astrazeneca
AZN
Mkt Cap317.5B
AstraZeneca PLC has a strong presence in oncology, respiratory, and cardiovascular diseases, competing with Chugai's research and drug portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap122.85B
Bristol-Myers Squibb Company competes in the oncology sector, particularly in developing treatments for cancer, a key area for Chugai.
GSK
GSK
Mkt Cap117.55B
GlaxoSmithKline plc competes with Chugai in the areas of oncology and immunology, with a focus on developing innovative medicines and vaccines.
Sanofi
SNY
Mkt Cap115.14B
Sanofi competes across several of the same therapeutic areas as Chugai, including oncology, immunology, and rare diseases.
Takeda Pharmaceutical
TAK
Mkt Cap56.3B
Takeda Pharmaceutical Company Limited, as a major Japanese pharmaceutical, competes directly with Chugai in the domestic market across various therapeutic areas including oncology and gastroenterology.

About

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
Show more...
CEO
Dr. Osamu Okuda
Employees
7664
Country
Japan
ISIN
JP3519400000

Listings

MX
MX
4519N.MX
STU
DE
CUP.STU
MU
DE
CUP.MU
MU
DE
CUP0.MU

0 Comments

Share your thoughts

FAQ

What is Chugai Pharmaceutical stock price today?▼
The current price of 4519.TSE is ¥8,815 JPY — it has increased by +0.63% in the past 24 hours. Watch Chugai Pharmaceutical stock price performance more closely on the chart.
What is Chugai Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Chugai Pharmaceutical stocks are traded under the ticker 4519.TSE.
Is Chugai Pharmaceutical stock price growing?▼
4519.TSE stock has risen by +2.04% compared to the previous week, the month change is a +10.9% rise, over the last year Chugai Pharmaceutical has showed a +7.55% increase.
What is Chugai Pharmaceutical market cap?▼
Today Chugai Pharmaceutical has the market capitalization of 14.8T
When is the next Chugai Pharmaceutical earnings date?▼
Chugai Pharmaceutical is going to release the next earnings report on April 24, 2026.
What were Chugai Pharmaceutical earnings last quarter?▼
4519.TSE earnings for the last quarter are 76.27 JPY per share, whereas the estimation was 72.3 JPY resulting in a +5.48% surprise. The estimated earnings for the next quarter are N/A JPY per share.
What is Chugai Pharmaceutical revenue for the last year?▼
Chugai Pharmaceutical revenue for the last year amounts to 2.34T JPY.
What is Chugai Pharmaceutical net income for the last year?▼
4519.TSE net income for the last year is 774.63B JPY.
Does Chugai Pharmaceutical pay dividends?▼
Yes, 4519.TSE dividends are paid semi-annual. The last dividend per share was 75 JPY. As of today, Dividend Yield (FWD)% is 1.51%.
How many employees does Chugai Pharmaceutical have?▼
As of April 23, 2026, the company has 7,664 employees.
In which sector is Chugai Pharmaceutical located?▼
Chugai Pharmaceutical operates in the Health & Wellness sector.
When did Chugai Pharmaceutical complete a stock split?▼
The last stock split for Chugai Pharmaceutical was on June 29, 2020 with a ratio of 3:1.
Where is Chugai Pharmaceutical headquartered?▼
Chugai Pharmaceutical is headquartered in Tokyo, Japan.